Carumonam
Chemical compound
- J01DF02 (WHO)
- 2-[(Z)-[1-(2-Amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-(carbamoyloxymethyl)-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid
- 87638-04-8 Y
- 6540466
- DB13553 Y
- 5022832 Y
- 486890PI06
- CHEBI:55486
- ChEMBL1614658 Y
- DTXSID3048312
- Interactive image
- C1=C(N=C(S1)N)/C(=N/OCC(=O)O)/C(=O)N[C@H]2[C@H](N(C2=O)S(=O)(=O)O)COC(=O)N
InChI
- InChI=1S/C12H14N6O10S2/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21)16-8-5(1-27-12(14)23)18(10(8)22)30(24,25)26/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26)/b17-7-/t5-,8+/m1/s1 Y
- Key:UIMOJFJSJSIGLV-JNHMLNOCSA-N Y
Carumonam (INN) is a monobactam antibiotic.[1] It is very resistant to beta-lactamases, which means that it is more difficult for bacteria to break down using β-lactamase enzymes.[2]
References
- ^ McNulty CA, Garden GM, Ashby J, Wise R (September 1985). "Pharmacokinetics and tissue penetration of carumonam, a new synthetic monobactam". Antimicrobial Agents and Chemotherapy. 28 (3): 425–7. doi:10.1128/aac.28.3.425. PMC 180266. PMID 4073864.
- ^ PubChem. "Carumonam". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-12-08.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Glycopeptides Lipoglycopeptides |
|
---|---|
Lipopeptides |
|
Polymyxins |
|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e